Drug therapy of high-risk lipid abnormalities in children and adolescents: A scientific statement from the American Heart Association atherosclerosis, hypertension, and obesity in youth committee, council of cardiovascular disease in the young, with the council on cardiovascular nursing

Brian W. McCrindle, Elaine M. Urbina, Barbara A. Dennison, Marc S. Jacobson, Julia Steinberger, Albert P. Rocchini, Laura L. Hayman, Stephen R. Daniels

Research output: Contribution to journalReview articlepeer-review

340 Scopus citations

Abstract

Despite compliance with lifestyle recommendations, some children and adolescents with high-risk hyperlipidemia will require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia. The purpose of this statement is to examine new evidence on the association of lipid abnormalities with early atherosclerosis, discuss challenges with previous guidelines, and highlight results of clinical trials with statin therapy in children and adolescents with familial hypercholesterolemia or severe hypercholesterolemia. Recommendations are provided to guide decision-making with regard to patient selection, initiation, monitoring, and maintenance of drug therapy.

Original languageEnglish (US)
Pages (from-to)1948-1967
Number of pages20
JournalCirculation
Volume115
Issue number14
DOIs
StatePublished - Apr 2007

Keywords

  • AHA Scientific Statements
  • Drugs
  • Hypercholesterolemia
  • Lipids
  • Pediatrics

Fingerprint Dive into the research topics of 'Drug therapy of high-risk lipid abnormalities in children and adolescents: A scientific statement from the American Heart Association atherosclerosis, hypertension, and obesity in youth committee, council of cardiovascular disease in the young, with the council on cardiovascular nursing'. Together they form a unique fingerprint.

Cite this